To further understand the molecular basis of the immune response elicited by these proteins. We focused on 9-mer long peptides since HLA class I binds 9-mers more frequently than 8, 10 or 11-mer peptides. Both LdEno and LdAld had 6 Yunaconitine epitopes for MHC class II epitopes while LdEno had 6 and LdAld had 5 epitopes for MHC Class I. To our knowledge, this is the first report regarding the potentiality of enolase �Ca glycolytic protein, as possible Atropine sulfate vaccine candidate against VL. In addition, in-silico analysis of LdAld and LdEno has suggested that LdAld and LdEno both can be potential vaccine candidates. During spring-summer 2009, several observational studies from Canada reported that prior receipt of the 2008�C09 trivalent inactivated influenza vaccine was associated with increased risk of medically-attended, laboratory-confirmed Apdm09 illness, with estimated risk or odds ratios of 1.4�C2.5 compared to those unvaccinated. This increased risk was not apparent among vaccinated people when comparing hospitalized to community cases, and observational studies in other settings showed contradictory results, including increased, null or protective effects from vaccination. Hypotheses to explain findings from Canada initially focused on methodologic or product-specific considerations. However, a randomized-controlled trial in Hong Kong spanning November 2008 to October 2009 also showed significantly increased relative risk among children who had received a different manufacturer’s 2008�C09 TIV product. Previous ferret studies have also shown mixed results although none have demonstrated 2008�C09 TIV to have been protective against Apdm09. Two small ferret studies reported no TIV effect on virus replication in nasal or lung specimens but, where clinical outcomes have been assessed, several studies have shown consistent albeit non-significant trend toward greater weight loss and worsening of severity indicators in vaccinated ferrets. All of these ferret studies to date, however, have suffered from small sample size, typically comparing #5 animals per group in total. Mechanistic hypotheses to explain increased Apdm09 risk among prior TIV recipients have included both direct and indirect vaccine effects. The direct effect hypothesis postulates that seasonal vaccine may directly influence host resistance to pandemic virus infection and/or replication whereas the indirect hypothesis proposes that seasonal vaccine may block the more robust, complex and cross-protective immunity otherwise afforded by seasonal virus infection thereby indirectly increasing the risk of pandemic illness. Here we report on a randomized, blinded, placebo-controlled ferret study to test whether the commerciallyavailable TIV predominantly used in Canada in 2008�C09 may have directly influenced Apdm09 disease risk. During spring-summer 2009, several observational studies from Canada reported that prior recipients of 2008�C09 TIV experienced approximately two-fold increased risk of medically-attended, laboratory-confirmed Apdm09 illness. Recognizing that all observational designs are susceptible to methodological bias, gold standard RCT analysis would typically be considered essential in clarifying such unexpected findings. In Hong Kong, an RCT of the 2008�C09 TIV already underway had shown similar association among vaccinated children with significant relative risk of 2.58 ; however, during follow-up RCT using 2009�C10 Vaxigrip and spanning August 2009 to December 2010, the same investigators instead reported significant protective effects. Both RCTs lacked sufficient power for analysis based on virologically-confirmed infection so that conclusions were drawn instead from less reliable serologically-defined outcomes.